Patrick A. Ott
0000-0002-4253-943X
Publication & Citation Trends
Most Cited Works
Publications
580 total
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment OA
Cited by 7
Semantic Scholar
Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma
Cited by 3
Semantic Scholar
Neoantigen-directed therapeutics in the clinic: where are we? OA
Cited by 27
Semantic Scholar
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy OA
Cited by 1
Semantic Scholar
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
Cited by 3
Semantic Scholar
Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma
Cited by 0
Semantic Scholar
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
Cited by 5
Semantic Scholar
Precision cancer medicine: Concepts, current practice, and future developments OA
Cited by 57
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(412)
Immunotherapy and Immune Responses
(268)
CAR-T cell therapy research
(107)
Immune cells in cancer
(105)
vaccines and immunoinformatics approaches
(58)
Frequent Co-Authors
Affiliations
The Wistar Institute
Broad Institute
Boston University
University of Toledo Medical Center
Brigham and Women's Hospital